Martin M. Okun

4.9k citations

47 papers · 3.0k indexed · 2 hit papers · h-index 25

Dermatology top 0.1%
Immunology top 1%
Surgery top 5%
Epidemiology top 5%
Rheumatology top 2%

Co-authors: Richard G. Langley Alexa B. Kimball Yihua Gu Kenneth B. Gordon Alan Menter Craig L. Leonardi Kim Papp Bruce Strober
Topics: Psoriasis: Treatment and Pathogenesis (23 papers)Dermatology and Skin Diseases (19 papers)Hidradenitis Suppurativa and Treatments (18 papers)
Cited by: Dermatology Immunology Complementary and Manual Therapy
Journals: Annals of Internal Medicine Journal of Virology American Journal of Obstetrics and Gynecology
Partner nations: United States Canada Germany

In The Last Decade

Martin M. Okun

45 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

2007 695 citations Alan Menter, Kenneth B. Gordon et al. Journal of the American Academy of Dermatology profile →
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

2012 305 citations Alexa B. Kimball, Francisco A. Kerdel et al. Annals of Internal Medicine profile →

Peers

Countries citing papers authored by Martin M. Okun

Since Specialization

Citations

This map shows the geographic impact of Martin M. Okun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin M. Okun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin M. Okun more than expected).

Fields of papers citing papers by Martin M. Okun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin M. Okun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin M. Okun. The network helps show where Martin M. Okun may publish in the future.

Co-authorship network of co-authors of Martin M. Okun

This figure shows the co-authorship network connecting the top 25 collaborators of Martin M. Okun. A scholar is included among the top collaborators of Martin M. Okun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin M. Okun. Martin M. Okun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The promise of personalized medicine for hidradenitis suppurativa 2022 ·British Journal of Dermatology ·Martin M. Okun	0
2	Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department 2022 ·Journal of Emergency Medicine ·Martin M. Okun,(unknown),(unknown),Joslyn S. Kirby	6
3	No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated 2022 ·PubMed ·(unknown),Martin M. Okun	0
4	Clinical Epidemiology and Management of Hidradenitis Suppurativa 2021 ·Obstetrics and Gynecology ·Christopher J. Sayed,Jennifer L. Hsiao,Martin M. Okun	13
5	Diagnosis and management of hidradenitis suppurativa in women 2020 ·American Journal of Obstetrics and Gynecology ·(unknown),(unknown),Michelle A. Lowes,Haley B. Naik,Martin M. Okun,Vivian Y. Shi,(unknown)	13
6	Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study 2018 ·Journal of the American Academy of Dermatology ·Christos C. Zouboulis,Martin M. Okun,Errol P. Prens,Robert Gniadecki,Peter Foley,Charles Lynde,Jamie Weisman,Yihua Gu,David Williams,Gregor B. E. Jemec	136
7	Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial 2017 ·Journal of the American Academy of Dermatology ·Boni E. Elewski,Martin M. Okun,Kim Papp,Christopher Baker,Jeffrey Crowley,G. Guillet,Murali Sundaram,Yves Poulin,Yihua Gu,Ziqian Geng,David Williams,Phoebe Rich	68
8	Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials 2017 ·Journal of the American Academy of Dermatology ·Kenneth B. Gordon,Keith A. Betts,Murali Sundaram,James Signorovitch,Junlong Li,Meng Xie,Eric Q. Wu,Martin M. Okun	6
9	006 Therapeutic response guided dosing strategy to optimize long-term adalimumab treatment in patients with hidradenitis suppurativa: integrated results from the PIONEER phase 3 trials 2016 ·Journal of Investigative Dermatology ·Wayne Gulliver,Martin M. Okun,Antonio Martorell,(unknown),Xin Huang,Qi Tang,David Williams,Y. Gu	4
10	Phase 1 studies of anti-interleukin-1 dual-variable domain immunoglobulin in healthy subjects and patients with osteoarthritis 2015 ·Osteoarthritis and Cartilage ·(unknown),(unknown),Ping Jiang,Martin M. Okun,Richard A. Preston,Carlos J. Lozada,(unknown),Jan Paul Medema	2
11	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa 2012 ·Annals of Internal Medicine ·Alexa B. Kimball,Francisco A. Kerdel,David R. Adams,Ulrich Mrowietz,Joel M. Gelfand,Robert Gniadecki,Errol P. Prens,Joel Schlessinger,Christos C. Zouboulis,Hessel H. van der Zee,(unknown),Parvez Mulani,Yihua Gu,Susan K. Paulson,Martin M. Okun,Gregor B. E. Jemec	7
12	Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study 2012 ·British Journal of Dermatology ·C. Leonardi,Jeffrey M. Sobell,Jeffrey Crowley,Ulrich Mrowietz,Yanjun Bao,Parvez Mulani,Y. Gu,Martin M. Okun	34
13	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativabreakdown → 2012 ·Annals of Internal Medicine ·Alexa B. Kimball,Francisco A. Kerdel,David R. Adams,Ulrich Mrowietz,Joel M. Gelfand,Robert Gniadecki,Errol P. Prens,Joel Schlessinger,Christos C. Zouboulis,Hessel H. van der Zee,(unknown),Parvez Mulani,Yihua Gu,Susan K. Paulson,Martin M. Okun,Gregor B. E. Jemec	305
14	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study 2011 ·Journal of the American Academy of Dermatology ·Bruce Strober,Yves Poulin,Francisco A. Kerdel,Richard G. Langley,Yihua Gu,Shiraz R. Gupta,Martin M. Okun,Kim Papp	53
15	Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy 2010 ·British Journal of Dermatology ·Kim Papp,Jeffrey Crowley,J.‐P. Ortonne,Jocelyn H. Leu,Martin M. Okun,(unknown),(unknown),Richard G. Langley	92
16	Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities 2010 ·American Journal of Clinical Dermatology ·Alexa B. Kimball,Arielle G. Bensimon,Annie Guérin,Andrew P. Yu,Eric Q. Wu,Martin M. Okun,Yanjun Bao,Shiraz R. Gupta,Parvez Mulani	55
17	Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis 2010 ·British Journal of Dermatology ·Richard G. Langley,Bruce Strober,Y. Gu,Stephen J. Rozzo,Martin M. Okun	30
18	Psoriasis Area and Severity Index: Nuts and bolts of measuring disease severity in psoriasis 2008 ·Clinics in Dermatology ·Martin M. Okun	7
19	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study 2006 ·Journal of the American Academy of Dermatology ·Kenneth B. Gordon,Richard G. Langley,Craig L. Leonardi,Darryl Toth,Alan Menter,Sewon Kang,Michael Heffernan,Bruce Miller,(unknown),(unknown),Judy Zhong,Rebecca L. Hoffman,Martin M. Okun	407
20	A quinine-induced drug reaction of photosensitive distribution with histological features mimicking mycosis fungoides 1994 ·Clinical and Experimental Dermatology ·Martin M. Okun,(unknown),(unknown)	7

About Martin M. Okun

Martin M. Okun is a scholar working on Dermatology, Immunology and Complementary and Manual Therapy, having authored 47 papers that have together received 3.0k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (23 papers), Dermatology and Skin Diseases (19 papers) and Hidradenitis Suppurativa and Treatments (18 papers). The work is most often cited by research in Dermatology (2.0k citations), Immunology (1.9k citations) and Complementary and Manual Therapy (64 citations). Martin M. Okun has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Richard G. Langley, Alexa B. Kimball, Yihua Gu, Kenneth B. Gordon, Alan Menter, Craig L. Leonardi, Kim Papp, Bruce Strober, Martin Kaul and Stephen K. Tyring. Their work appears in journals such as Annals of Internal Medicine, Journal of Virology and American Journal of Obstetrics and Gynecology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact